Startups
Circassia is a dedicated diagnostics and monitoring company focused on respiratory disease. Our market-leading NIOX® products are used by physicians around the world to help improve asthma diagnosis and management, and we support our customers through our dedicated teams in the United States, Europe and China and our network of global partners.
Our purpose is to improve the quality of life for millions of people suffering from respiratory diseases.
As the leading provider of point-of-care FeNO monitoring and measurement products we are making good progress, helping healthcare professionals manage their patients’ asthma.
We believe every asthma patient should have access to the best care. To help achieve this, we are working hard to provide our customers with outstanding support, while devoting ourselves to developing the next generation of NIOX® innovations.
*LungFit PH is not an approved name for the product and may not be the final name submitted for approval.
Our purpose is to improve the quality of life for millions of people suffering from respiratory diseases.
As the leading provider of point-of-care FeNO monitoring and measurement products we are making good progress, helping healthcare professionals manage their patients’ asthma.
We believe every asthma patient should have access to the best care. To help achieve this, we are working hard to provide our customers with outstanding support, while devoting ourselves to developing the next generation of NIOX® innovations.
*LungFit PH is not an approved name for the product and may not be the final name submitted for approval.
Overview
Location
United Kingdom, England, Oxford
Employees
201-500
Founded date
2006
Mentions in press and media 9
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Mar 24, 2021 | Circassia : PRELIMINARY RESULTS FOR THE YEAR ENDED 31 DECEMBER 2020 | PRELIMINARY RESULTS FOR THE YEAR ENDED 31 DECEMBER 2020 Oxford, UK - 24 March 2021: Circassia Group plc ('Circassia' or the 'Company' and, together with its subsidiaries, the 'Group') (LSE: CIR) today announces... |
| Mar 24, 2021 | CIRCASSIA GROUP PLC Circassia : PRELIMINARY RESULTS FOR THE YEAR ENDED 31 DECEMBER 2020 | PRELIMINARY RESULTS FOR THE YEAR ENDED 31 DECEMBER 2020 Oxford, UK - 24 March 2021: Circassia Group plc ('Circassia' or the 'Company' and, together with its subsidiaries, the 'Group') (LSE: CIR) today announces... |
| Aug 16, 2019 | Bain's Orly Mishan joins Pfizer's neuro spinout Cerevel; Oncolytic virus biotech taps SillaJen exec Helena Chaye as CEO | Orly Mishan → Bain Capital is deploying one of its top investors to Cerevel Therapeutics, steering a $350 million-plus neuro play carved out of Pfizer. Orly Mishan — a co-founder and principal of Bain’s life sciences uni... |
| Apr 18, 2017 | A final flop signals the bitter end to Circassia’s big plans for allergy R&D | Circassia CEO Steve Harris Remember the big plans Circassia {LSE: CIR} had for its allergy drug pipeline when it went public, raising $333 million in 2014 with promises of big things to come for investors? It didn’t work out. ... |
| Aug 31, 2016 | Startup Spirometrix readies connected asthma sensors for market | “Prevention. That’s the story we’re about,” Zikria said. The Pleasanton, California-based startup has built two models of the breathalyzers. The Fenom Home, about the size of a can of soda but with a mouthpiece, is for personal home use, wh... |
| Jun 20, 2016 | Circassia shares crumble as PhIII flop blights the sector once again | When Circassia Pharmaceuticals went public on the London Stock Exchange two years ago, raising a whopping $300 million, the British biotech community brimmed with enthusiasm over the prospect of revived investor intere... |
| Startup Spirometrix readies connected asthma sensors for market | Sensors are everywhere — our cars, our refrigerators, our TVs and, of course, our smartphones, which generate more bits of data about us on given day than there are stars in the sky. However there is one frontier where sensors have been mis... | |
| INVEST Pitch Perfect winner: myBiometry aims to prevent asthma attacks long before they happen | The novel technology at the heart of myBiometry’s asthma solution is a patented sensor (top right) and device (center) that measures nitric oxide, a biomarker of airway inflammation, in breath. This is used to determine if an individual is ... |
Reviews 0
FAQ about Circassia
When was Circassia founded?
Circassia was founded in 2006.
What has the press written about Circassia?
Parsers VC has collected 9 articles mentioning Circassia, among them “Circassia : PRELIMINARY RESULTS FOR THE YEAR ENDED 31 DECEMBER 2020” (Mar 24, 2021) and “CIRCASSIA GROUP PLC Circassia : PRELIMINARY RESULTS FOR THE YEAR ENDED 31 DECEMBER 2020” (Mar 24, 2021).
Is Circassia still active?
Yes, Circassia is active; its latest activity on Parsers VC dates from Mar 4, 2024.